Technical Analysis for KURA - Kura Oncology, Inc.

Grade Last Price % Change Price Change
F 12.775 -1.58% -0.21
KURA closed up 4.51 percent on Tuesday, December 7, 2021, on 1.43 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical KURA trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup -1.58%
Spinning Top Other -1.58%
Wide Bands Range Expansion -1.58%
Oversold Stochastic Weakness -1.58%
New 52 Week Low Weakness 2.86%
Wide Bands Range Expansion 2.86%
Oversold Stochastic Weakness 2.86%
New 52 Week Closing Low Bearish 3.11%
Stochastic Reached Oversold Weakness 3.11%
Wide Bands Range Expansion 3.11%
Older End-of-Day Signals for KURA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % 29 minutes ago
Down 1% 29 minutes ago
60 Minute Opening Range Breakout about 21 hours ago
1.5x Volume Pace 1 day ago
Rose Above Previous Day's High 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kura Oncology, Inc. Description

Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Cancers Oncology Lymphoma Thyroid Backup Carcinoma Signal Transduction Oncogenes Cell Signaling Protein Kinase Acute Leukemia Blood Cancers Kras Leukemias Benzamides Ras Subfamily

Is KURA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 42.72
52 Week Low 12.02
Average Volume 592,333
200-Day Moving Average 21.53
50-Day Moving Average 17.11
20-Day Moving Average 15.58
10-Day Moving Average 13.72
Average True Range 0.90
ADX 38.89
+DI 13.09
-DI 37.41
Chandelier Exit (Long, 3 ATRs) 17.02
Chandelier Exit (Short, 3 ATRs) 14.72
Upper Bollinger Bands 19.69
Lower Bollinger Band 11.47
Percent B (%b) 0.18
BandWidth 52.78
MACD Line -1.37
MACD Signal Line -1.07
MACD Histogram -0.3075
Fundamentals Value
Market Cap 736.07 Million
Num Shares 56.7 Million
EPS -1.57
Price-to-Earnings (P/E) Ratio -8.28
Price-to-Sales 0.00
Price-to-Book 7.39
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.20
Resistance 3 (R3) 14.18 13.74 14.00
Resistance 2 (R2) 13.74 13.43 13.75 13.93
Resistance 1 (R1) 13.36 13.24 13.55 13.39 13.86
Pivot Point 12.93 12.93 13.02 12.94 12.93
Support 1 (S1) 12.55 12.61 12.74 12.57 12.10
Support 2 (S2) 12.11 12.42 12.12 12.03
Support 3 (S3) 11.73 12.11 11.96
Support 4 (S4) 11.76